[Form 4] ATAI Life Sciences N.V. Insider Trading Activity

Rhea-AI Filing Summary

Atai Beckley N.V. (ATAI) reported insider activity on November 5, 2025. A director received several stock option grants: three fully vested options at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 common shares with expirations from July 2025 to October 2032, and an additional 103,000 options at $4.48 expiring in November 2035 that vest on the first anniversary of the grant date.

On the same date, the company completed its acquisition of Beckley Psytech Limited, issuing 103,000,066 common shares as consideration or as underlying replacement awards pursuant to the purchase agreement.

Insights

Equity capital markets analyst

Large share issuance for acquisition; option grants mostly time-based.

ATAI closed the Beckley Psytech acquisition on Nov 5, 2025, issuing 103,000,066 common shares as consideration or underlying replacement awards. This is a significant equity-based transaction that increases the share count and reflects stock-settled deal mechanics.

Insider compensation disclosed the same day includes stock options: three grants at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 shares, each fully vested at grant, expiring between 2030 and 2032; plus 103,000 options at $4.48 expiring in 2035, vesting on the first anniversary. These are standard time‑based awards.

Potential effects depend on post-close integration and future disclosures. Actual dilution impact follows from the 103,000,066-share issuance; option exercises depend on market price versus the $1.35 and $4.48 strikes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERSHBERG ROBERT

(Last) (First) (Middle)

C/O ATAI BECKLEY N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183AT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atai Beckley N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.35	11/05/2025		A		456,011(1)		(2)	07/05/2030	Common Shares	456,011	$0	456,011	D
Stock Option	$1.35	11/05/2025		A		97,716(1)		(2)	06/07/2030	Common Shares	97,716	$0	97,716	D
Stock Option	$1.35	11/05/2025		A		62,394(1)		(2)	10/20/2032	Common Shares	62,394	$0	62,394	D
Stock Option	$4.48	11/05/2025		A		103,000		(3)	11/05/2035	Common Shares	103,000	$0	103,000	D

Explanation of Responses:

1. On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.

2. The stock option is fully vested as of the grant date.

3. The stock option shall vest in full on the first anniversary of the grant date.

	/s/ Ryan Barrett, as attorney in fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ATAI report on the Form 4?

A director reported stock option grants on November 5, 2025: three fully vested options at $1.35 for 456,011, 97,716, and 62,394 shares, plus 103,000 options at $4.48.

What are the vesting terms of the ATAI options disclosed?

The $1.35 options are fully vested at grant; the 103,000 options at $4.48 vest in full on the first anniversary of the grant date.

When do the ATAI options expire?

The $1.35 options expire between July 2030 and October 2032; the $4.48 options expire on November 5, 2035.

Did ATAI complete the Beckley Psytech acquisition?

Yes. On November 5, 2025, ATAI completed the acquisition of Beckley Psytech, issuing 103,000,066 common shares as consideration or underlying replacement awards.

What is ATAI’s ticker symbol?

ATAI.